The ‘SaaSpocalypse’ Isn’t Here. Healthcare Buyers Are Spending More — But AI Now Has to Prove ROI.

Bain & Company and KLAS surveyed 303 US healthcare executives and found technology spending remains resilient — with roughly 95% of providers and payers placing software and digital technology among their top five strategic priorities. For RCM vendors, the more important finding is that AI experimentation is giving way to an ROI test.

Healthcare Is Not Pulling Back From Technology

Despite investor fears that generative AI could commoditize software, Bain and KLAS found most healthcare organizations expect technology spending to increase. Nearly 95% of providers and payers rank software and digital technology among their top five strategic priorities.

RCM Is Still Near the Top of the Budget

Revenue cycle remains a top-three investment priority for 43% of acute providers and 64% of ambulatory providers in the survey. Denial management and clinical documentation improvement are highlighted as focus areas as providers respond to increasing payer automation.

That is a meaningful demand signal for the RCM AI market: financial pressure is not eliminating investment. It is directing dollars toward workflows with measurable revenue or cost outcomes.

AI May Strengthen Incumbents, Not Destroy Them

One of the report's more consequential findings cuts against the “AI kills SaaS” narrative. Nearly 80% of acute provider organizations surveyed believe generative AI will either increase switching costs or have no impact on them.

Providers also continue to favor EHR-native products in workflows close to the clinical core. That suggests AI can deepen incumbent moats when the incumbent owns the data, workflow and distribution required to deploy it.

The Point-Solution Bar Is Rising

This does not mean emerging RCM AI vendors lose. It means they need sharper proof. Buyers increasingly want a defined use case, short time to value and measurable economics. “We use AI” is rapidly becoming table stakes.

The strongest opportunities remain workflows where labor is expensive, reimbursement impact is visible and the vendor can demonstrate outcomes quickly — exactly why denials, CDI, prior authorization and claims workflows continue attracting investment.

What This Means for RCAI's Market

The market is separating into strategic platforms and high-ROI specialists. Vendors caught between those positions may face the greatest pressure.

For investors and operators, that is the key takeaway from the Bain/KLAS data: healthcare IT demand remains strong, but capital is becoming more disciplined. AI has not ended healthcare software. It has raised the standard for what software must deliver.